Mansfield, MA, June 12, 2018 —

Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes, presented data this past week at the American Transplant Congress (ATC; Seattle; June 2-‐6) from clinical utility studies demonstrating the value of TruGraf testing to support physician decisions regarding kidney transplant patient care, and reduce the reliance on surveillance biopsies.

“TruGraf is the first test capable of providing information to physicians that a patient with stable renal function and no clinical signs of rejection is indeed healthy, and does not need an invasive and costly surveillance biopsy. Data presented at ATC from our Early Access Program (EAP) partner transplant centers indicate clinical utility of TruGraf testing as a non-‐invasive alternative to surveillance “protocol” biopsies to confirm immune quiescence in kidney transplant recipients with stable renal function,” stated Dr. M. Roy First, Chief Medical Officer at TGI. Over 200 clinicians and scientist attended TGI’s luncheon symposium where study data was presented from independent transplant centers emphasizing clinical utility of TruGraf v1, followed by presentations describing initial results from the NIH funded CTOT-‐08 study involving use of TruGraf v2 which is designed to specifically rule out the presence of sub-‐clinical acute rejection in kidney transplant recipients with stable renal function. The symposium was highlighted by the following presentations:

Value of TruGraf testing in sites not performing surveillance biopsies
V. Ram Peddi MD, California Pacific Medical Center

Correlation of the TruGraf test and renal biopsy result
Richard Knight MD, Houston Methodist Hospital

Potential for the TruGraf test to reduce surveillance biopsies
Roz Mannon MD, University of Alabama Birmingham

A New Blood Biomarker Allows Detection and Treatment Monitoring for
Sub-‐Clinical Rejection -‐ A New Paradigm
John Friedewald MD, Northwestern University

The association of subclinical acute rejection, diagnosed by surveillance biopsy or the TruGraf test, and the development of de novo DSA in the CTOT-‐08 study
Ray Heilman MD, Mayo Clinic

“ATC is the leading transplant conference to present new clinical tools aimed at improving health management of transplant recipients. TGI was thrilled with the positive response from clinicians regarding the data supporting clinical utility of TruGraf v1, the first blood-‐based test validated for confirming immune quiescence in stable patients, prior to any suspicion of graft damage becoming evident”, said Stan Rose, PhD, CEO of Transplant Genomics.

But the greatest amount of enthusiasm was expressed following the TruGraf v2 presentations during the luncheon symposium (also covered in several posters and an oral presentation) highlighting the first non-‐invasive test validated for stratifying stable patients likely to harbor sub-‐clinical acute rejection,” added Dr. Rose.

MEDIA CONTACT:
Darren Lee
781-454-6523
dlee@transplantgenomics.com

About Transplant Genomics Inc.

Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immune-‐ suppressive therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA lab in Pleasanton, CA. www.transplantgenomics.com; www.trugraf.com.